Supplementary Table 1. Difference in baseline charactheristics of patients accepting participation in the follow up study and those rejecting participation

|  |  |  |  |
| --- | --- | --- | --- |
|  | Accepted Participation | Rejected Participation | p |
| n (%) | 46 (63.9%) | 26 (36.1%) | - |
| Age (year) | 63.8 (±6.5) | 61.5 (±8.9) | 0.20 |
| Sex (male) | 37 (80.4%) | 19(73.1%) | 0.52 |
| AHI (events/hour) | 37.8 (±16.0) | 30.9(±13.0) | 0.07 |
| Diabetes duration (year) | 16.1 (±9.3) | 14.6 (±7.7) | 0.50 |
| Systolic BP (mmHg) | 143.9 (±15.3) | 138.6 (±17.5) | 0.19 |
| Diastolic BP (mmHg) | 83.3 (±7.8) | 80.4 (±9.8) | 0.17 |
| cfPWV (m/s) | 10.7 (±2.0) | 11.1 (±2.2) | 0.50 |
| BMI (kg/m2) | 34.7 (±3.9) | 34.3 (±5.1) | 0.69 |
| HbA1c (mmol/mol) | 66.7 (±8.9) | 66.3 (±3.9) | 0.84 |
| Fasting blood glucose (mmol/l) | 9.4 (±2.6) | 9.8 (±1.9) | 0.43 |
| Smoking* Currently (n (%))
* Former (n (%))
* Never (n (%))
 | 6 (13%)18 (39.1%)22 (47.8%) | 4 (15.4%)9 (34.6%)13 (50%) | 0.92 |
| Antidiabetic medication* No medication (n (%))
* Metformin (n (%))
* Insulin (n (%))
* GLP1 analog (n (%))
* DPP4 inhibitor (n (%))
* SGLT2 inhibitor (n (%))
* Sulphonyl Urea (n (%))
 | 3 (6.5%)26 (78.3%)29 (63.0%)27 (58.7%)3 (6.5%)5 (10.9%)1 (2.2%) | 0 (0%)22 (84.6%)18 (69.2%)12 (46.2%)4 (15.4%)8 (30.8%)1 (3.8%) | 0.180.510.600.310.22**0.04**0.68 |
| Blood pressure medication* No medication (n (%))
* Beta blockers (n (%))
* Thiazide (n (%))
* ACE-inhibitor (n (%))
* AT2 antagonist (n (%))
* Calcium blockers (n (%))
* Loop diuretics (n (%))
* Other (n (%))
 | 4 (8.7%)18 (39.1%)19 (41.3%)24 (52.2%)14 (30.4%)18 (39.1%)8 (17.4%)7 (15.2%) | 2 (4.3%)10 (38.5%)9 (34.6%)11 (42.3%)10 (38.5%)11 (42.3%)2 (4.3%)2 (4.3%) | 0.880.960.580.420.490.790.250.35 |
| Statin use (n(%)) | 36 (78.3%) | 21 (80.8%) | 0.56 |
| Asprin use (n(%)) | 25 (54.3%) | 12 (46.2%) | 0.61 |

Abbreviations: BP, blood pressure; cfPWV, carotid-femoral pulse wave velocity; GLP1, glucagon like peptide; DPP4, di-peptidyl peptidase 4; SGLT2, sodium-glucose co-transporter 2; ACE, angiotensin converting enzyme; AT2, angiotensin-